AI medical imaging firm Gleamer has acquired two developers of AI-powered MRI applications, Pixyl and Caerus Medical.
The acquisitions of the two firms add MRI to Gleamer’s portfolio of radiology applications covering x-ray, mammography, and CT, giving the firm a suite of AI-based tools for all core imaging modalities, the company said. Financial and other details of the acquisitions were not disclosed.
Pixyl is the developer of Pixyl.Neuro, which is CE-marked and has been cleared as a Class IIa medical device by the U.S. Food and Drug Administration (FDA). Pixyl.Neuro enables the early detection of neuroinflammatory and neurodegenerative conditions, including Alzheimer’s disease.
Caerus Medical’s technology, LumbarMR, uses AI to detect lumbar disorders (such as disc herniation, stenosis, and spondylolisthes) on MRI scans, supporting radiologists and physicians in improving the diagnosis.
Gleamer noted that its workforce will surpass 100 employees in seven countries with the acquisition of the two firms; all three companies are based in Paris.